Close Menu

NEW YORK (GenomeWeb) — Regulus Therapeutics this week released interim results from an ongoing Phase I study of its microRNA-targeting hepatitis C therapy RG-101, which showed that a single subcutaneous dose of the drug could trigger an average 4.1-log reduction in viral loads in patients — a number on par with current treatments.

On the better-than-expected data, shares of Regulus rocketed up more than 115 percent, hitting $14.60 during Wednesday afternoon trading on the Nasdaq.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

In Nature this week: the largest known collection of human genetic variants, and more.